隐球菌性脑膜炎的免疫学发病机制

doi:10.3969/j.issn.1004-583X.2021.05.014

摘要/Abstract

摘要：

隐球菌是一种嗜神经性的机会性致病真菌,隐球菌性脑膜炎(cryptococcal meningitis, CM)是极为凶险的中枢神经系统感染性疾病,治疗困难,病死率高。本文从隐球菌侵入中枢神经系统、免疫应答机制及免疫治疗方面进行系统阐述。

关键词: 脑膜炎, 隐球菌性, 变态反应和免疫学, 免疫疗法

中图分类号:

R515.2

孙伟, 朱运辉, 许佳敏, 王羚, 宋萍萍, 张玉生. 隐球菌性脑膜炎的免疫学发病机制[J]. 临床荟萃, 2021, 36(5): 458-461.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.05.014

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I5/458

参考文献 49

[1]	Maziarz EK, Perfect JR. Cryptococcosis[J]. Infect Dis Clin North Am, 2016, 30(1):179-206. doi: 10.1016/j.idc.2015.10.006 URL
[2]	May RC, Stone NR, Wiesner DL, et al. Cryptococcus: From environmental saprophyte to global pathogen[J]. Nat Rev Microbiol, 2016, 14(2):106-117. doi: 10.1038/nrmicro.2015.6 URL
[3]	Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: Epidemiology, immunology, diagnosis and therapy[J]. Nat Rev Neurol, 2016, 13(1):13-24.
[4]	Shimizu H, Hara S, Nishioka H. Disseminated cryptococcosis with granuloma formation in idiopathic cd4 lymphocytopenia[J]. J Infect Chemother, 2020, 26(2):257-260. doi: S1341-321X(19)30208-9 pmid: 31345742
[5]	Zaragoza O. Basic principles of the virulence of cryptococcus[J]. Virulence, 2019, 10(1):490-501. doi: 10.1080/21505594.2019.1614383 pmid: 31119976
[6]	Coelho C, Casadevall A. Cryptococcal therapies and drug targets: The old, the new and the promising[J]. Cell Microbiol, 2016, 18(6):792-799. doi: 10.1111/cmi.v18.6 URL
[7]	Franco-Paredes C, Womack T, Bohlmeyer T, et al. Management of cryptococcus gattii meningoencephalitis[J]. Lancet Infect Dis, 2015, 15(3):348-355. doi: 10.1016/S1473-3099(14)70945-4 pmid: 25467646
[8]	Anjum S, Williamson PR. Clinical aspects of immune damage in cryptococcosis[J]. Curr Fungal Infect Rep, 2019, 13(3):99-108. doi: 10.1007/s12281-019-00345-7 URL
[9]	Leopold Wager CM, Hole CR, Wozniak KL, et al. Cryptococcus and phagocytes: Complex interactions that influence disease outcome[J]. Front Microbiol, 2016, 7:105.
[10]	Panackal AA, Williamson KC, van de Beek D, et al. Fighting the monster: Applying the host damage framework to human central nervous system infections[J]. mBio, 2016, 7(1):e01906-e01915.
[11]	Liu TB, Perlin DS, Xue C. Molecular mechanisms of cryptococcal meningitis[J]. Virulence, 2012, 3(2):173-181. doi: 10.4161/viru.18685 URL
[12]	Klein RS, Hunter CA. Protective and pathological immunity during central nervous system infections[J]. Immunity, 2017, 46(6):891-909. doi: 10.1016/j.immuni.2017.06.012 URL
[13]	Colombo AC, Rodrigues ML. Fungal colonization of the brain: Anatomopathological aspects of neurological cryptococcosis[J]. An Acad Bras Cienc, 2015, 87(2 Suppl):1293-1309. doi: 10.1590/0001-3765201520140704 URL
[14]	Jong A, Wu CH, Shackleford GM, et al. Involvement of human cd44 during cryptococcus neoformans infection of brain microvascular endothelial cells[J]. Cell Microbiol, 2008, 10(6):1313-1326. doi: 10.1111/j.1462-5822.2008.01128.x URL
[15]	Vu K, Eigenheer RA, Phinney BS, et al. Cryptococcus neoformans promotes its transmigration into the central nervous system by inducing molecular and cellular changes in brain endothelial cells[J]. Infect Immun, 2013, 81(9):3139-3147. doi: 10.1128/IAI.00554-13 URL
[16]	Na Pombejra S, Salemi M, Phinney BS, et al. The metalloprotease, mpr1, engages annexina2 to promote the transcytosis of fungal cells across the blood-brain barrier[J]. Front Cell Infect Microbiol, 2017, 7:296. doi: 10.3389/fcimb.2017.00296 URL
[17]	Charlier C, Chrétien F, Baudrimont M, et al. Capsule structure changes associated with cryptococcus neoformans crossing of the blood-brain barrier[J]. Am J Pathol, 2005, 166(2):421-432. doi: 10.1016/S0002-9440(10)62265-1 URL
[18]	Posey JE, Harel T, Liu P, et al. Resolution of disease phenotypes resulting from multilocus genomic variation[J]. N Engl J Med, 2017, 376(1):21-31. doi: 10.1056/NEJMoa1516767 URL
[19]	Santiago-Tirado FH, Onken MD, Cooper JA, et al. Trojan horse transit contributes to blood-brain barrier crossing of a eukaryotic pathogen[J]. mBio, 2017, 8(1):e02183-e021816.
[20]	Casadevall A, Coelho C, Alanio A. Mechanisms of cryptococcus neoformans-mediated host damage[J]. Front Immunol, 2018, 9:855. doi: 10.3389/fimmu.2018.00855 pmid: 29760698
[21]	Rudman J, Evans RJ, Johnston SA. Are macrophages the heroes or villains during cryptococcosis?[J]. Fungal Genet Biol, 2019, 132:103261. doi: S1087-1845(19)30204-X pmid: 31415906
[22]	Heung LJ. Innate immune responses to Cryptococcus[J]. J Fungi (Basel), 2017, 3(3):35.
[23]	Mukaremera L, Nielsen K. Adaptive immunity to cryptococcus neoformans infections[J]. J Fungi (Basel), 2017, 3(4):64.
[24]	Campuzano A, Wormley FL. Innate immunity against cryptococcus, from recognition to elimination[J]. J Fungi (Basel), 2018, 4(1):33.
[25]	Bojarczuk A, Miller KA, Hotham R, et al. Cryptococcus neoformans intracellular proliferation and capsule size determines early macrophage control of infection[J]. Sci Rep, 2016, 6:21489. doi: 10.1038/srep21489 URL
[26]	Fu MS, Drummond RA. The diverse roles of monocytes in cryptococcosis[J]. J Fungi (Basel), 2020, 6(3):111.
[27]	Hansakon A, Jeerawattanawart S, Pattanapanyasat K, et al. Il-25 receptor signaling modulates host defense against cryptococcus neoformans infection[J]. J Immunol, 2020, 205(3):674-685. doi: 10.4049/jimmunol.2000073 pmid: 32561567
[28]	LaRocque-de-Freitas IF, Rocha JDB, Nunes MP, et al. Involvement of the capsular galxm-induced il-17 cytokine in the control of cryptococcus neoformans infection[J]. Sci Rep, 2018, 8(1):16378. doi: 10.1038/s41598-018-34649-4 pmid: 30401972
[29]	Heung LJ. Monocytes and the host response to fungal pathogens[J]. Front Cell Infect Mi, 2020, 10:34. doi: 10.3389/fcimb.2020.00034 pmid: 32117808
[30]	Subramani A, Griggs P, Frantzen N, et al. Intracellular cryptococcus neoformans disrupts the transcriptome profile of m1-and m2-polarized host macrophages[J]. PLoS One, 2020, 15(8):e0233818. doi: 10.1371/journal.pone.0233818 URL
[31]	Goldman DL, Khine H, Abadi J, et al. Serologic evidence for cryptococcus neoformans infection in early childhood[J]. Pediatrics, 2001, 107(5):E66. doi: 10.1542/peds.107.5.e66 URL
[32]	Chen LC, Goldman DL, Doering TL, et al. Antibody response to cryptococcus neoformans proteins in rodents and humans[J]. Infect Immun, 1999, 67(5):2218-2224. pmid: 10225877
[33]	Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in thailand and taiwan[J]. N Engl J Med, 2012, 367(8):725-734. doi: 10.1056/NEJMoa1111160 URL
[34]	Schulze B, Piehler D, Eschke M, et al. Cd4(+) foxp3(+) regulatory t cells suppress fatal t helper 2 cell immunity during pulmonary fungal infection[J]. Eur J Immunol, 2014, 44(12):3596-3604. doi: 10.1002/eji.201444963 pmid: 25187063
[35]	Schulze B, Piehler D, Eschke M, et al. Therapeutic expansion of cd4+foxp3+ regulatory t cells limits allergic airway inflammation during pulmonary fungal infection[J]. Pathog Dis, 2016, 74(4):ftw020.
[36]	Wiesner DL, Smith KD, Kotov DI, et al. Regulatory t cell induction and retention in the lungs drives suppression of detrimental type 2 th cells during pulmonary cryptococcal infection[J]. J Immunol, 2016, 196(1):365-374. doi: 10.4049/jimmunol.1501871 pmid: 26590316
[37]	Arora S, Olszewski MA, Tsang TM, et al. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with cryptococcus neoformans[J]. Infect Immun, 2011, 79(5):1915-1926. doi: 10.1128/IAI.01270-10 URL
[38]	Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in hiv-associated cryptococcal meningitis[J]. PLoS Pathog, 2015, 11(4):e1004754. doi: 10.1371/journal.ppat.1004754 URL
[39]	Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the cryptococcus-specific cd4+ memory t-cell response is associated with disease severity and outcome in hiv-associated cryptococcal meningitis[J]. J Infecti Dis, 2013, 207(12):1817-1828.
[40]	Pirofski LA, Casadevall A. The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases[J]. J Infecti Dis, 2018, 218(suppl_1):S7-s11.
[41]	Panackal AA, Wuest SC, Lin YC, et al. Paradoxical immune responses in non-hiv cryptococcal meningitis[J]. PLoS Pathogens, 2015, 11(5):e1004884. doi: 10.1371/journal.ppat.1004884 URL
[42]	Henao-Martínez AF, Chastain DB, Franco-Paredes C. Treatment of cryptococcosis in non-hiv immunocompromised patients[J]. Curr Opin Infect Dis, 2018, 31(4):278-285. doi: 10.1097/QCO.0000000000000458 pmid: 29738314
[43]	Wager CML, Hole CR, Campuzano A, et al. Ifn-gamma immune priming of macrophages in vivo induces prolonged stat1 binding and protection against cryptococcus neoformans[J]. PLoS Pathogens, 2018, 14(10):e1007358. doi: 10.1371/journal.ppat.1007358 URL
[44]	Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in hiv-associated cryptococcal meningitis[J]. N Engl J Med, 2016, 374(6):542-554. doi: 10.1056/NEJMoa1509024 URL
[45]	Lane M, McBride J, Archer J. Steroid responsive late deterioration in cryptococcus neoformans variety gattii meningitis[J]. Neurology, 2004, 63(4):713-714. doi: 10.1212/01.WNL.0000134677.29120.62 URL
[46]	Leopold Wager CM, Wormley FL. Is development of a vaccine against cryptococcus neoformans feasible?[J]. PLoS Pathogens, 2015, 11(6):e1004843. doi: 10.1371/journal.ppat.1004843 URL
[47]	He ZT. Macrophage-mediated innate immunity for the treatment of cryptococcal meningitis[J]. Aip Conf Proc, 2020, 2208.
[48]	Caballero Van Dyke MC, Wormley FL. A call to arms: Quest for a cryptococcal vaccine[J]. Trends Microbiol, 2018, 26(5):436-446. doi: S0966-842X(17)30229-9 pmid: 29103990
[49]	Leopold Wager CM, Hole CR, Campuzano A, et al. IFN-γ immune priming of macrophages in vivo induces prolonged stat1 binding and protection against cryptococcus neoformans[J]. PLoS Pathog, 2018, 14(10):e1007358. doi: 10.1371/journal.ppat.1007358 URL

隐球菌性脑膜炎的免疫学发病机制

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘婉琦, 樊树芹, 庄瑞雪, 贺峰, 刘振川, 解忠祥. 成人水痘-带状疱疹病毒相关颅内感染5例临床分析[J]. 临床荟萃, 2024, 39(2): 149-154.
[2]	王瑶, 黄鹏如, 曾昭豪, 罗宏, 岑海媚, 罗彬, 张誉. 以步态不稳为首发症状的新型隐球菌性脑膜脑炎1例[J]. 临床荟萃, 2023, 38(3): 260-263.
[3]	汪露, 曾昭豪, 罗宏, 岑海媚, 张誉. 肥厚性硬脑膜炎2例并文献分析[J]. 临床荟萃, 2021, 36(7): 637-640.
[4]	齐雪姣a，卜晖a，邹月丽a，杨建凯b，赵银龙b，何俊瑛a. 难治性真菌性脑膜炎3例并文献复习[J]. 临床荟萃, 2019, 34(2): 154-157.
[5]	李淑敏，李垚，蔺建文，任彦微，宋其生，郝国华，王苏平. 结核性脑膜炎抗结核菌纯蛋白衍生物抗体与脑脊液细胞学的相关性[J]. 临床荟萃, 2018, 33(5): 402-404,408.
[6]	杨志国，张妮，杨保旺，李兴川，王静，王海东. 小儿化脓性脑膜炎并发惊厥的危险因素[J]. 临床荟萃, 2017, 32(7): 602-605.
[7]	周文，李莉娟，王文媛，许丽丽，张连生. 急性髓系白血病中树突状细胞疫苗的免疫治疗[J]. 临床荟萃, 2017, 32(6): 549-552.
[8]	许丽丽，李莉娟，周文，王文媛，张连生. 髓源性抑制细胞在肿瘤治疗中的相关研究及应用前景[J]. 临床荟萃, 2017, 32(6): 545-548.
[9]	刘洋,李莉娟,马愔花,刘树梅,张连生. 骨髓增生异常综合征中树突状细胞的免疫异常与免疫治疗------现状与前景[J]. 临床荟萃, 2016, 31(5): 573-576,580.
[10]	马愔花, 李莉娟, 刘树梅, 刘洋, 张连生. 免疫治疗在多发性骨髓瘤中的研究进展[J]. 临床荟萃, 2016, 31(4): 447-450.
[11]	何萍，徐俊，丰涛，王运中，陶云珍，房锐颖，邵雪军，朱宏. 儿童中枢神经系统感染脑脊液主要病原菌的构成及耐药性的监测[J]. 临床荟萃, 2016, 31(10): 1121-1124.
[12]	尹光芝;苏慧勇;张国丽;杨磊;尹世明. 43例获得性免疫缺陷综合征合并隐球菌脑膜炎临床特点分析[J]. 临床荟萃, 2015, 30(4): 404-407.
[13]	杜彭;巩路. 新型隐球菌性脑膜炎12例临床分析[J]. 临床荟萃, 2015, 30(1): 86-88.
[14]	杨士斌;唐晓娜;陈源;张会丰. 以化脓性脑膜炎为首发表现的不完全川崎病1例[J]. 临床荟萃, 2014, 29(5): 559-559.
[15]	席学莉. 隐球菌病合并脑梗死1例[J]. 临床荟萃, 2014, 29(12): 1422-0.